Hansoh Pharmaceutical Group's (HKG:3692) antibody-drug conjugate HS-20093 received another breakthrough therapy designation (BTD) from China's National Medical Products Administration.
This new designation aims to benefit HS-20093's development as a treatment for locally advanced or metastatic non-squamous non-small cell lung cancer without driver mutations, which has progressed or recurred following platinum-based chemotherapy.
HS-20093 was previously granted BTDs for extensive-stage small-cell lung cancer that developed after standard first-line treatment and for osteosarcoma in patients with disease progression after at least two prior lines of therapy, according to a Thursday filing with the Hong Kong Exchange.
Drug candidates with BTD status gain advantages like potential conditional approval and priority review, accelerating their development for serious diseases with limited treatment options.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.